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Mice modelAbstract Background: Preclinical models that mimic pathological and molecular features of
solitary fibrous tumour (SFT) represent an important tool to select effective regimes and novel
compounds to be tested in the clinic. This study was aimed at developing two preclinical
models of SFT, assessing their predictive value in the clinic and selecting potential novel effec-
tive treatments.
Material and methods: Two dedifferentiated-SFT (D-SFT) models obtained from patients’ bi-
opsies were grown in immunodeficient mice. The antitumour activity on these models of doxo-
rubicin, dacarbazine (DTIC), ifosfamide (monotherapy or combination), trabectedin and
eribulin was tested. Twelve SFT patients were treated with doxorubicin and DTIC. Response
by RECIST, progression-free survival and overall survival were retrospectively evaluated, dis-
tinguishing malignant-SFT (M-SFT) and D-SFT.
Results: Two D-SFT patient-derived xenografts (PDXs) that represent the first available pre-
clinical in vivo models of SFT were developed and characterised. Doxorubicin/DTIC, DTIC/
ifosfamide, doxorubicin/ifosfamide combinations consistently induced better antitumour ac-
tivity than the single-agents. Particularly, doxorubicin/DTIC combination caused a max
tumour volume inhibition >80% in both models. Doxorubicin/DTIC combo showed activity
also in the case-series. Best RECIST responses were: 6 responses (M-SFT Z 2 of 7, D-
SFT Z 4 of 5), 1 stable disease, 5 progressions, with a 6-month median progression-free sur-
vival (M-SFT Z 6, D-SFT Z 10 months). The PDXs were very sensitive to trabectedin and
eribulin.
Conclusion: Doxorubicin plus DTIC combination was effective in our two D-SFT mice
models and appeared to be active also in the clinic, especially in high-grade D-SFT patients.
Among additional drugs tested in the PDXs, trabectedin and eribulin were highly effective,
providing a rational to test these drugs in D-SFT patients.
ª 2017 Elsevier Ltd. All rights reserved.1. Introduction
Solitary fibrous tumour (SFT) is a rare sarcoma [1,2],
marked by a recurrent NAB2-STAT6 gene fusion that is
responsible for the nuclear expression of the transcrip-
tion factor STAT6 [3]. Three clinical-pathologic variants
of SFT are identified: typical (T-SFT), malignant (M-
SFT) and dedifferentiated (D-SFT) SFT [1,4]. M-SFT is
marked by a greater mitotic index (4/10 HPF)
compared with T-SFT. D-SFT shows the transition to a
high-grade morphology. Notably, STAT6 nuclear
immunopositivity can be lost in D-SFT [5]. SFT has a
low metastatic potential (15%), but a greater meta-
static rate (40%) is observed in D-SFT [6,7].
Preliminary evidence is available that both anthra-
cyclines and temozolomide are effective in SFT [8,9]. We
had already tested the activity of temozolomide and
dacarbazine (DTIC) in a patient-derived xenograft
(PDX) model of high-grade SFT, confirming that they
looked equally active [10]. In the same paper we re-
ported 8 patients undergoing DTIC, with 3 responses.
The good consistency observed between preclinical
and clinical observations encouraged us to develop
further this approach. In this study, we report the
development and characterisation of two preclinical
models of SFT and the results of the experiments aimed
at comparing the activity of cytotoxic agents currently
used for treatment of soft tissue sarcoma, including thedoxorubicin-DTIC combination, trabectedin and eri-
bulin. We also assessed retrospectively the clinical ac-
tivity of doxorubicin in combination with DTIC in a
small population of advanced SFT patients.
2. Materials and methods
2.1. Experimental models and pharmacological studies
Two D-SFT PDX models were used in the study.
2.1.1. Development and characterisation of the model
The models were established by subcutaneous grafting
of tumour fragments obtained at the time of surgery
from 2 patients into the right flank of female SCID
(SFT-1) or nude (SFT-2) mice (Charles River, Calco,
IT). Specifically, SFT-1 was established from a pleo-
morphic osteochondro-like D-SFT from a patient with
recurrent pelvic D-SFT [4]. Both in the patient and in
the PDX, the tumour carried the NAB2-STAT6 fusion
transcript (ex6.INT6.ex3int), as detected by RT-PCR
[3], but lacked immunohistochemical nuclear STAT6
expression [5]. SFT-2 was derived from a patient with
locally relapsed D-SFT, pre-treated with sunitinib. This
tumour closely resembled an Ewing sarcoma/peripheral
primitive neuroectodermal tumour [4]. It was charac-
terised by NAB2-STAT6 fusion transcript (ex6.ex18)
and negative STAT6 immunohistochemistry [5]. This
S. Stacchiotti et al. / European Journal of Cancer 76 (2017) 84e9286PDX showed superimposable morphology and, by
contrast, recovered STAT6 nuclear expression (Suppl.
Fig. 1). Both PDXs showed MGMT methylation [10].
SFT-1 carried a hemizygous and SFT-2 a homozygous
RB1 deletion, as assessed by FISH with BACs mapping
on RB1 locus (RP11-305D15, RP11-174I10) together
with a control on 13q 31.3 (RP11-121J7) [5]. TP53 was
mutated in SFT-2. 17p deletion, including the TP53
gene, was observed in both clinical tumours by CGH
array [5] (Table 1).
Tumour growth was followed by biweekly measure-
ment of tumour diameters with a Vernier calliper, and
tumour volume (TV) calculated by the following for-
mula: TV (mm3) Z d2 X D/2, where d and D are the
shortest and the longest diameter, respectively.
The xenograft origin was authenticated through mi-
crosatellite analysis [10].
The use of patient material to generate xenografts
and all experiments were approved by the institutional
Ethics Committees for Animal Experimentation.
2.1.2. Xenograft treatments
Treatments started when xenografts were approximately
300 mm3. Eight mice for experimental group were used.Table 1
Molecular features of patient tumours and corresponding PDX models.
Sample Diagnosis NAB2-STAT6
fusion transcript
STAT6 nuclear
immunopositivity
Human
sample 1
Pleomorphic
osteochondro-like
dedifferentiated-SFT
þ 
SFT-1 þ 
Human
sample 2
Ewing-like
dedifferentiated-SFT
þ 
SFT-2 þ þ
Abbreviations: SFT, solitary fibrous tumour; nd, not done; WT, wild type
Table 2
Pharmacological treatments and tumour responses of PDXs treated with d
singly administered and in combination.
Treatment Dose (mg/kg) Schedule
Doxorubicin 2.5 q7d  4
IFO 90 qd  3 q 2w
DTIC 105 q7d  4
Doxorubicin/DTIC 2.5
105
q7d  4
q7d  4
IFO/DTIC 90
105
qd  3 q 2w
q7d  4
IFO/doxorubicin 90
2.5
qd  3 q 2w
q7d  4
IFO/doxorubicin/DTIC 90
2.5
105
qd  3 q 2w
q7d  4
q7d  4
Trabectedin 0.15 q7d  3
Eribulin 1 q4d  3 q3w
Abbreviations: SFT, solitary fibrous tumour; TVI, tumour volume inhibit
a Maximum tumour volume inhibition% in treated versus control mice.After dilution in sterile water (doxorubicin, DTIC,
ifosfamide) or saline solution (trabectedin, eribulin),
drugs were administered at dosage-schedules reported in
Table 2. Treatment activity was assessed determining
TV inhibition percentage (TVI%) in treated versus
control mice, expressed as TVI% Z 100  ([mean TV
treated/mean TV control]  100).2.1.3. Immunohistochemical assessment of g-H2AX
expression
The immunohistochemical assessment of g-H2AX was
performed on FFPE PDX samples obtained 24 h after
the first drug treatment and stained with the anti-
phospho-H2AX (Ser139) mouse monoclonal antibody
(Millipore).2.1.4. Western blotting
Lysates from frozen PDX tumours obtained at the end
of the last eribulin treatment were prepared [11]. Pro-
teins were separated by SDS-PAGE, transferred onto
nitrocellulose membranes and incubated with primary
monoclonal antibodies, anti-MPM2, anti-cyclin B1,
anti-phospho Cdk1 (Tyr15) and anti-b-actin [12].MGMT promoter
methylation
RB1 TP53
array CGH [4]
TP53 mutation
analysis
þ Hemyzigous
deletion
Hemyzigous
deletion
WT
þ Hemyzigous
deletion
nd WT
þ Homozygous
deletion
Hemyzigous
deletion
G245S
þ Homozygous
deletion
nd G245S
.
oxorubicin, dacarbazine (DTIC), ifosfamide (IFO) and trabectedin,
Route SFT-1 SFT-2
Max TVI%a Max TVI%a
i.v. 27 (83) 29 (98)
i.p. 45 (90) 44 (98)
i.p. 54 (97) 55 (94)
i.v.
i.p.
83 (90) 96 (98)
i.p.
i.p.
74 (97) 96 (98)
i.p.
i.v.
68 (97) 93 (98)
i.p.
i.v.
i.p
97 (97) e
i.v. 70 (90) 98 (103)
i.p. 92 (77) e
ion; i.v., intravenous; i.p., intraperitoneal.
In parentheses, the day on which it was assessed.
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We retrospectively identified 12 patients affected by
advanced SFT treated with doxorubicin plus DTIC
within 3 centres of the Italian Rare Cancer Network
from February 2012 to July 2016. All patients provided
a written informed consent to the treatment.
Diagnosis was confirmed by expert sarcoma pathol-
ogists, according to the WHO classification [1] and
updated criteria [6], reviewing the available tumour
sample closest to the start of chemotherapy. STAT6
immunohistochemistry was performed [5]. Seven cases
were consistent with M-SFT and 5 with D-SFT.
Table 3 summarises patient characteristics.
Patients received doxorubicin (75 mg/mq, i.v., bolus)
and DTIC (800 mg/mq, intravenously over 60 min, in 2
days), every 3 weeks, until a maximum of 6 cycles, un-
acceptable toxicity or progression. Adverse events were
recorded. Disease status was assessed at baseline by a
whole body computed tomography scan (CT), a CT or
magnetic resonance (MR) of the site(s) of disease, and a
whole body bone scan. CT/magnetic resonance scans
were repeated every 2 cycles. Response was assessed by
RECIST 1.1.
Progression-free survival (PFS) and overall survival
(OS) were estimated with KaplaneMeyer method.
Failure for PFS was progressive disease by RECIST,
or death. Failure for OS was death due to any cause.
Patients alive were censored at the time of the last
contact.T
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P3. Results
3.1. Experimental model and pharmacological studies
The antitumour activity of doxorubicin, DTIC and
ifosfamide, administered as monotherapy or in combi-
nation, was tested against late-stage SFT-1 and SFT-2
xenografts. As monotherapy, DTIC and ifosfamide
induced a significant and superimposable tumour
growth inhibition in SFT-1 and SFT-2, whereas an
almost negligible antitumour activity was observed
following doxorubicin treatment in both models (Fig. 1,
Table 2). Notably, drugs were delivered at suboptimal
doses to highlight the effects of the combined treat-
ments. Doxorubicin/DTIC, DTIC/ifosfamide and
doxorubicin/ifosfamide combinations consistently
induced an enhanced antitumour activity compared with
single-agents, which was mainly appreciable in SFT-2,
as indicated by max TVI (mTVI) always >90% and
long-lasting tumour regressions observed in all mice
(Fig. 1, Table 2). Although to a lesser extent, an
enhanced therapeutic effect of the two-drug combina-
tions was also observed in the SFT-1, in particular with
the doxorubicin/DTIC combination (mTVI Z 83%). In
SFT-1, the three-drug combination (doxorubicin/DTIC/
Fig. 1. Antitumour activity of doxorubicin (DOXO), dacarbazine (DTIC), ifosfamide (IFO), trabectedin and eribulin, singly administered
and in combination, against solitary fibrous tumours xenotransplanted into SCID (SFT-1) and nude (SFT-2) mice. SFT, solitary fibrous
tumour.
S. Stacchiotti et al. / European Journal of Cancer 76 (2017) 84e9288ifosfamide) induced the almost complete regression of
tumours (mTVI Z 97%; Fig. 1, Table 2).
The expression of g-H2AX, a specific marker for
monitoring treatment-induced DNA damage [13], was
increased in tumours exposed to the two-drug combi-
nations compared with individual agents in both xeno-
grafts (Fig. 2A, Suppl. Fig. 2). A further enhancement
was observed in SFT-1 PDXs after treatment with
doxorubicin/DTIC/ifosfamide combination (Fig. 2A).
Trabectedin monotherapy induced an mTVI Z 70%
in SFT-1, whereas an mTVI Z 98% was detected in
SFT-2, which was appreciable until two months from the
end of treatment (Fig. 1, Table 2). g-H2AX expression
levels indicated that trabectedin caused less DNA dam-
age (Fig. 2A, Suppl. Fig. 2) than doxorubicin/DTIC,
DTIC/ifosfamide and doxorubicin/ifosfamide combina-
tions, consistent with the notion that trabectedin activity
is mainly related to the effect on transcription regulation
[14].Eribulin activity, tested only against SFT-1, induced
an mTVI Z 92%, with 4 mice experiencing long-lasting
complete responses, 2 of which were maintained until
the end of the experiment (Fig. 1).
Biochemical analysis on eribulin-treated xenografts
showed increased staining of MPM-2 antibody, which
recognises mitotic phosphoproteins [15], together with
enhanced cyclin B1 levels and dephosphorylation on
inhibitory Tyr-15 of Cdk1 [16], consistent with a tumour
cell accumulation in the G2/M phase (Fig. 2B).
3.2. Patients
Twelve patients with advanced SFT received doxoru-
bicin combined with DTIC. Mean number of cycles was
5. The treatment was well tolerated and toxicity was as
expected (Table 3).
All patients were assessable for response. The best
RECIST response was partial response (PR) in 6 (50%),
Fig. 2. A) g-H2AX nuclear immunostaining in SFT-1 tumours following exposure to doxorubicin (DOXO), dacarbazine (DTIC), ifos-
famide (IFO) and trabectedin, singly administered and in combination. B) Western blot analysis of mitosis-related factors in SFT-tumour
following exposure to eribulin. SFT, solitary fibrous tumour.
S. Stacchiotti et al. / European Journal of Cancer 76 (2017) 84e92 89stable disease in 1 (8.3%) and progression in 5 (41.7%)
cases (Table 3, Fig. 3). A RECIST PR was detected in 2/
7 M-SFT and in 4/5 D-SFT.
At a 25-month median follow-up, the median OS was
19 months (range 9e44þ), with 7 patients dead at the
time of the analysis. The median PFS was 6 months
(range 2e32), with 20% of patients progression-free at12 months. Median PFS was 6 and 10 in M-SFT and D-
SFT, respectively (p Z 0.37).
4. Discussion
No prospective studies focussing on chemotherapy are
available in SFT. Of course, their rarity makes
Fig. 3. Axial, contrast enhanced CT scans in a man affected by lung metastases (red arrows) from a dedifferentiated solitary fibrous
tumour of the glutaeus, at baseline (left panel) and after 6 cycles of treatment with doxorubicin and DTIC (right panel). The lung lesions in
the middle lobe reduced from 12 to 10 mm to 6 and 5 mm, respectively, thus achieving a partial response according to RECIST. SFT,
solitary fibrous tumour; DTIC, dacarbazine. (For interpretation of the references to colour in this figure legend, the reader is referred to
the web version of this article.)
S. Stacchiotti et al. / European Journal of Cancer 76 (2017) 84e9290comparative assessments in clinical studies challenging.
Thus, retrospective series and predictive preclinical
models are important to select treatments to be pro-
spectively tested in clinical trials. PDX models, obtained
through the direct implant in immunodeficient mice of
surgical tumour specimens, are particularly promising,
since they retain the main molecular, genetic and his-
tologic features of donor tumours, closely recapitulating
the original heterogeneity [17]. An advantage of PDXs
compared with cell-linedederived xenografts is their
ability to better predict the response to therapeutic
agents and to provide the insights useful for drug
scheduling [18].
We already reported the consistency between pre-
clinical and clinical results concerning the activity of
temozolomide and DTIC [10] as well as that of several
antiangiogenics [19] in our first D-SFT model (SFT-1).
These results prompted us to develop further models
and to compare the activity of the cytotoxic drugs
available for treatment of sarcomas.
By assessing the activity of doxorubicin, ifosfamide
and DTIC (as monotherapy or in combination) in two
D-SFT PDXs, we observed that all combinations
consistently induced an increased antitumuor activity
compared with single-agents. Such an enhancement was
mainly appreciable with the doxorubicin/DTIC combi-
nation (mTVIsZ 83% and 96% observed in SFT-1 and
SFT-2, respectively). Interestingly, the three-drug com-
bination doxorubicin/DTIC/ifosfamide induced an
almost complete regression of SFT-1 xenograft tumours.
The increased antitumour activity was parallelled by an
enhanced gH2AX staining in tumours, thus indicating
the cumulative induction of lethal DNA lesions as a
main mechanism responsible for the therapeutic efficacy
of the combinations.
It is noteworthy that in these preclinical experiments
suboptimal doses of individual agents were used to
better appreciate the effect of combos. However, a
remarkable therapeutic effect was also appreciable whenhigher doses of DTIC [10] or doxorubicin (Suppl. Fig. 3)
were used as single-agents. This may be relevant for less
fit and/or elder patients when a disease stabilisation is
acceptable and a monotherapy with an expected better
toxicity profile can be the choice.
Available data on the role of chemotherapy in pa-
tients with SFT are limited and point to the activity of
agents like anthracycline, DTIC, ifosfamide [20,21] and
trabectedin [22,23]. Two responses to eribulin were also
reported [24,25]. The expected RR is low both with
anthracycline-based regimens (0e20%) and with tra-
bectedin (9%) [8,21,23,24,26e28]. In 2013, we published
a retrospective series of 31 SFT patients treated with
anthracycline-based chemotherapy (anthracycline mon-
otherapy: 8; anthracycline/ifosfamide: 23). We observed
20% RECIST PR and a 4-month median PFS [8].
Notably, PRs were found in 2/18 (11%) M-SFT e 4/12
(30%) D-SFT, with a median PFS of 3.5 and 5 months
in M-SFT and D-SFT, respectively. The finding that the
doxorubicin/DTIC combination was active in our D-
SFT models prompted us to assess the efficacy of this
combination in the clinic. The case-series analysis that
we could collect and present herein, with all the limita-
tions of a small and retrospective series of patients,
confirms that anthracycline-based regimens are effective
in SFT, showing that the combination of doxorubicin/
DTIC seems to increase both the RR (50% PR by
RECIST) and PFS (6-month median PFS) compared
with our prior series. As already observed [8], D-SFT
appears more sensitive to chemotherapy compared with
M-SFT, both in terms of RR and of PFS (10 versus 6
months). This suggests preferring a combination of
doxorubicin/DTIC in high-grade cases and when a
major tumour response is needed.
In the D-SFT models, we also tested the activity of
other drugs of clinical interest for sarcomas, such as
trabectedin and eribulin.
Trabectedin showed remarkable antitumour activity
in both models. Indeed, a major (SFT-1) or almost
S. Stacchiotti et al. / European Journal of Cancer 76 (2017) 84e92 91complete (SFT-2) tumour regression was found, in
contrast with clinical data that are more consistent with
a disease stabilisation without tumour shrinkage [22].
Since clinical reports do not detail which is the SFT
subtype of those patients who benefited from trabecte-
din, the possibility that SFT biologic aggressiveness is
responsible for a different sensitivity to the drug cannot
be ruled out.
An impressive antitumour activity, with long-lasting
complete tumour regressions, was also observed in SFT-1
following treatment with the novel microtubule inhibitor
eribulin [29]. Consistently with its antimitotic effect,
biochemical analysis on eribulin-treated xenografts was
suggestive of tumour cell accumulation in the G2/M
phase. Eribulin was recently approved by FDA and EMA
for treatment of advanced liposarcoma resistant to
anthracycline, basedon the results of a phase 3 trial [30]. In
two phase 2 studies that were run in soft tissue sarcoma,
two anecdotal responses were detected in a SFT patients
[24,25]. This preliminary clinical observation, together
with the impressive preclinical results, suggests evaluating
further eribulin in SFT.
In conclusion, our results provide insights into the
activity of cytotoxic agents available in the clinical
practice for treatment of STS, confirming that, espe-
cially in the more aggressive SFT, they actually belong
to the therapeutic medical armamentarium. Based on
these results, a prospective phase 2 randomised study on
doxorubicin/DTIC versus trabectedin in advanced SFT
is starting. In addition, eribulin, the last cytotoxic agent
approved for the treatment of sarcoma, deserves further
investigations. Finally, additional experiments are
ongoing in our PDXs to investigate the efficacy of new
molecular targeted agent as single-agents and in com-
bination with cytotoxics in the disease.Conflict of interest statement
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